Background-Adipose harbors a large depot of free cholesterol. However, a role for adipose in cholesterol lipidation of high-density lipoprotein (HDL) in vivo is not established. We present the first evidence that adipocytes support transfer of cholesterol to HDL in vivo as well as in vitro and implicate ATP-binding cassette subfamily A member 1 (ABCA1) and scavenger receptor class B type I (SR-BI), but not ATP-binding cassette subfamily G member 1 (ABCG1), cholesterol transporters in this process. Methods and Results-Cholesterol efflux from wild-type, ABCA1
L ow plasma high-density lipoprotein (HDL) cholesterol (HDL-C) is a key feature of obesity and insulin resistance 1 and has a strong inverse relationship with atherosclerotic cardiovascular disease. 2 Reduced cholesterol lipidation of nascent HDL results in small, immature lipoprotein particles that are rapidly catabolized and excreted in the kidney. Thus, lipidation of HDL plays a role in supporting the atheroprotective functions of HDL in vivo. 3 
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Lipidation of HDL is determined via a number of cholesterol transporters in several cholesterol-rich tissues. Although macrophage cholesterol efflux to HDL plays a major role in attenuating atherosclerosis, macrophages play a minor role in regulation of HDL-C levels. 4 In contrast, hepatic ATPbinding cassette subfamily A member 1 (ABCA1), through lipidation of apolipoprotein A-I (apoA-I), is required for formation of nascent HDL particles. 5 Indeed, in cholesterolrich tissues, both hepatic and extrahepatic, ABCA1 has discrete and essential roles in the maintenance of plasma HDL-C. 6, 7 ATP-binding cassette subfamily G member 1 (ABCG1) mediates cholesterol efflux from macrophages to mature HDL particles 8, 9 and may play a role in regulating plasma HDL-C levels. 10 In contrast to ABC transporters, scavenger receptor class B type I (SR-BI) is a bidirectional transporter that plays a major role in hepatic uptake of HDL cholesterol ester. 11, 12 Although SR-BI is not believed to be important in macrophage cholesterol efflux to HDL, 13 a role in lipidating HDL via other peripheral SR-BI-expressing tissues 14 has not been examined. In fact, the relative role of tissues, beyond liver, in HDL lipidation requires further definition.
Adipose tissue contains a very large pool of free cholesterol. 15, 16 In fact, adipocytes are known to support cholesterol efflux to HDL and apoA-I in vitro. 17, 18 Recent work shows that ABCA1 and SR-BI are expressed in mature adipocytes, and adipocyte cholesterol homeostasis may be regulated in a cell-specific manner. 19 -21 Adipocyte cholesterol, therefore, represents a uniquely regulated and abundant depot for modulation of HDL-C levels. By extension, adipose inflammatory dysfunction in insulin-resistant states may impair adipocyte HDL lipidation and reduce circulating HDL-C levels in such settings.
In this study, we demonstrate that adipocytes are a regulated source of cholesterol transfer to HDL both in vitro and in vivo. In contrast to liver and macrophages, adipocyte cholesterol efflux is controlled by ABCA1 and SR-BI, but not ABCG1, and is suppressed, in a differentiation-dependent manner, by tumor necrosis factor-␣ (TNF-␣), an inflammatory adipocytokine. In summary, we report a novel, adipocyte-dependent mechanism of cholesterol transfer to HDL that may uniquely contribute to reduced plasma HDL-C in adipose inflammatory settings.
Methods

Cell Culture
3T3L1 cells were differentiated to adipocytes as described previously 22 (see online-only Data Supplement). Efflux studies were performed on days 0, 5, and 10 after differentiation. Mouse embryonic fibroblasts (MEFs) were isolated from 13.5-to 14.5-day embryos as described 23 (online-only Data Supplement). MEFs were grown to confluence before addition of differentiation media (as for 3T3L1 except addition of 1 mol/L of peroxisome proliferator-activated receptor-␥ agonist GW347845). Human Simpson-Golabi-Behmel syndrome (SGBS) adipocytes were cultured as described previously 24 (see online-only Data Supplement). Bone marrow macrophages (BMMs) were isolated from mouse femurs and tibias and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 30% L929-conditioned medium. 13 
Cholesterol Efflux Studies
Fully differentiated ABCA1 Ϫ/Ϫ , ABCG1 Ϫ/Ϫ , SR-BI Ϫ/Ϫ , and littermate, wild-type control MEFs as well 3T3L1 and SGBS adipocytes were labeled with 3 H-cholesterol (5 Ci/mL) (Perkin-Elmer Analytic Sciences, Boston, Mass) for 24 hours. Wild-type BMMs were labeled with 5 Ci/mL 3 H-cholesterol and loaded with 25 g/mL acetylated low-density lipoprotein for 24 hours. After equilibration, 3 H-cholesterol efflux from adipocytes and BMMs to apoA-I (20 g/mL), HDL3 (50 g/mL), 5% human (for SGBS cells) or 5% mouse (for 3T3L1, MEF, and BMM cells) serum, and MEM control was assessed over 4 hours as described previously for macrophages. 25 In MEF adipocyte studies, cells were equilibrated overnight in MEM containing 0.2% bovine serum albuminϮliver X receptor (LXR) agonist (10 mol/L). Cells were subsequently cotreated with LXR agonist ϮBLT (10 mol/L) or Ϯprobucol (20 mol/L) for 2 hours before efflux. The effect of TNF-␣ (10 ng/mL overnight) on cholesterol efflux from 3T3L1 cells was assessed at day 0 (preadipocyte), day 5 (Ϸ50% differentiated), or day 10 (mature) of adipocyte differentiation. Cell lipid was extracted with isopropanol, and total cellular 3 H-cholesterol was measured by liquid scintillation counting. Percent efflux to acceptors, minus MEM, is presented.
Adipocyte Transfer of Cholesterol to HDL In Vivo
We employed a modification of our published in vivo macrophageto-HDL reverse cholesterol transport (RCT) model. 12 
Effects of Inflammation on Expression of Cholesterol Transporters in Adipose
Female C57BL/6 mice were injected intravenously with 10 g/kg lipopolysaccharide, and after 6 hours, mice were euthanized by cervical dislocation. Adipose tissue was harvested. RNA and protein were isolated, and messenger RNA (mRNA) and protein expression of cholesterol transporters were assessed by real-time polymerase chain reaction and Western blotting, respectively (online-only Data Supplement).
General Laboratory Methods
A description of laboratory methods including lipoprotein analysis, quantitative real-time polymerase chain reaction, immunoblot analysis, and Oil red O staining is presented in the online-only Data Supplement.
Statistical Analysis
Data are reported as meanϮSEM. For experiments with multiple treatments, ANOVA was used to test for differences in group means. For mouse experiments with multiple time points, we performed 2-way repeated-measures ANOVA to test for differences in means between groups. When ANOVA was significant, post hoc Bonferroni-corrected t tests were applied. For comparison of data between 2 groups at a single time point (liver, bile, feces, mRNA data), unpaired t tests were performed. GraphPad Prism 5 (GraphPad Software Inc, San Diego, Calif) and Stata 9.0 software (Stata Corp, College Station, Tex) were used for statistical analyses. Statistical significance is presented as *PϽ0.05, **PϽ0.01, and ***PϽ0.001 in all figures.
Results
Cholesterol Content and Cholesterol Transporter Expression Increase During Adipocyte Differentiation
During 3T3L1 differentiation from fibroblasts to adipocytes ( Figure IA in the online-only Data Supplement), cellular cholesterol content increased Ϸ2-fold (Table IA in 
Mature Mouse and Human Adipocytes Efflux Cholesterol to HDL Acceptors
Mature murine (3T3L1) and human (SGBS) adipocytes supported cholesterol efflux to lipid acceptors apoA-I, HDL3, and serum ( Figure ID and IE in the online-only Data Supplement). Indeed, cholesterol efflux from mature adipocytes was comparable to that from BMMs in parallel efflux studies ( Figure IF in the online-only Data Supplement). Efflux to MEM from 3T3L1 (0.77Ϯ0.01%; nϭ3) and SGBS (0.42Ϯ0.044%; nϭ3) in the absence of acceptor was minimal.
Adipocyte Cholesterol Efflux Is Mediated via ABCA1 and SR-BI Transporters
ABCA1
Ϫ/Ϫ , ABCG1 Ϫ/Ϫ , SR-BI Ϫ/Ϫ , and littermate wild-type control MEFs were differentiated into adipocytes ( Figure IIA in the online-only Data Supplement), and cholesterol efflux studies were performed. Initially, the role of individual transporters was probed pharmacologically in wild-type MEF adipocytes. Probucol, an inhibitor of ABCA1-mediated efflux, 27 reduced cholesterol efflux from MEF adipocytes to apoA-I and abolished LXR-enhanced cholesterol efflux to apoA-I ( Figure 1A ). Cholesterol efflux to HDL3 was reduced by BLT, an inhibitor of SR-BI, 28 suggesting that adipocyte SR-BI mediates lipidation of mature HDL ( Figure 1B ). Similar to probucol effects ( Figure 1C , left panel), ABCA1 deficiency reduced efflux to apoA-I with complete attenuation of LXR-induced efflux to apoA-I ( Figure 1C , right panel). Probucol had no incremental effect on efflux to apoA-I in ABCA1 Ϫ/Ϫ adipocytes. In contrast, absence of ABCA1 had no impact on cholesterol efflux to HDL3 ( Figure  1D ). These data suggest that (1) ABCA1 plays a central role in adipocyte cholesterol efflux to apoA-I (consistent with macrophages 13 and liver 5, 29 ); (2) LXR-induced adipocyte cholesterol efflux is mediated via ABCA1; and (3) adipocyte ABCA1 plays a minor role in efflux to mature HDL. SR-BI deficiency had little effect on cholesterol efflux to apoA-I and did not influence inhibition of efflux to apoA-I by probucol ( Figure 1E ). Lack of adipocyte SR-BI, however, resulted in marked reduction in cholesterol efflux to HDL3 ( Figure 1F , right panel); this inhibition was almost identical to the BLT effect on efflux to HDL in wild-type adipocytes ( Figure 1F , left panel). BLT had no incremental effect on efflux to HDL in SR-BI Ϫ/Ϫ adipocytes. These data suggest that (1) SR-BI plays an important role in adipocyte cholesterol efflux to mature HDL particles (in contrast to findings in macrophages 13 ) and (2) SR-BI does not mediate basal or LXR-induced adipocyte cholesterol efflux to apoA-I.
ABCG1 Does Not Regulate Adipocyte Cholesterol Efflux In Vitro
ABCG1 has been implicated in cholesterol efflux from macrophages 8, 13 and liver. 10 Deficiency of ABCG1 in MEF adipocytes, however, had no effect on cholesterol efflux to any lipid acceptor ( Figure 2A ). As expected, real-time polymerase chain reaction analysis revealed a marked reduction in ABCG1 mRNA in knockout cells ( Figure 2B ). However, ABCG1 protein expression was barely detectable in fully differentiated wild-type MEF adipocytes ( Figure 2C ). In fact, real-time analysis in MEFs, 3T3L1 adipocytes (Table I in 
Adipocytes Can Transfer Cholesterol to HDL In Vivo
We modified our macrophage-to-feces RCT model 12, 26 to examine adipocyte-to-HDL transport of cholesterol in vivo. We labeled fully differentiated adipocytes with 3 H-cholesterol, injected labeled adipocytes intraperitoneally, and tracked movement of label onto plasma HDL and subsequently into liver and feces. First, we performed studies using 3T3L1 adipocytes injected into apoA-I transgenic, apoA-I deficient, or wild-type mice to establish proof of concept for this in vivo model. Movement of 3 H-cholesterol from intraperitoneally injected adipocytes to plasma increased steadily in the first 24 hours ( Figure 3A) , tracked with the HDL fraction in each group ( Figure 3C and 3D and Table 1 ), and resulted in detectable tracer in liver (not shown) and feces ( Figure 3B ). Overexpression of apoA-I increased plasma and HDL counts consistent with enhanced adipocyte-to-HDL cholesterol movement, whereas absence of apoA-I decreased plasma, HDL, and fecal counts, reflecting reduced movement of adipocyte label to HDL. Notably, the time course and extent of 3 H-cholesterol movement from adipocytes to HDL and through liver to feces were similar to our published findings for intraperitoneal injection of macrophage foam cells in apoA-I transgenic and null mice. 26, 30 These findings suggest that cholesterol movement from adipocytes into plasma in vivo is modulated by the circulating levels of HDL acceptor particles. H-cholesterol (5 Ci/mL), equilibrated, and then washed with PBS, and efflux to apoA-I (20 g/mL), HDL3 (50 g/mL), or 5% serum was monitored over 4 hours. RNA and protein were extracted. A, Efflux from wild-type and ABCG1
Ϫ/Ϫ to apoA-I, HDL3, and serum. B, ABCG1 mRNA levels were markedly reduced in ABCG1 Ϫ/Ϫ cells compared with wild-type control (nϭ3; ***PϽ0.001). C, ABCG1 protein levels were barely detectable in wild-type and ABCG1 Ϫ/Ϫ MEF adipocytes compared with positive control mouse liver lysate. 
Adipocyte ABCA1 and SR-BI Regulate Adipocyte Transfer of Cholesterol to HDL In Vivo
Movement of 3 H-cholesterol from intraperitoneally injected MEF adipocytes derived from ABCA1
Ϫ/Ϫ ( Figure 4A and 4B) and SR-BI Ϫ/Ϫ ( Figure 4C and 4D) mice into plasma, onto HDL, and into feces was significantly reduced compared with intraperitoneal injection of adipocytes derived from their wild-type littermates. As expected, the majority of plasma 3 H-cholesterol counts was associated with the HDL fraction ( Table 1 ). These studies indicate that adipocytes, acting via functional ABCA1 and SR-BI, can transfer cholesterol to HDL in vivo.
Inflammation Impairs Cholesterol Efflux From 3T3L1 Adipocytes
We examined whether TNF-␣, an inflammatory adipocytokine, 31 modulated 3T3L1 adipocyte cholesterol efflux to explore whether adipocyte lipidation of HDL might be reduced during adipose inflammation, a cornerstone of central adiposity and insulin resistance. 32, 33 Because inflammatory modulation of adipocyte functions may be differentiation dependent, 34, 35 we performed studies in preadipocytes (day 0) partially (day 5) and fully (day 10) differentiated adipocytes. Protein expression of ABCA1 and SR-BI cholesterol transporters increased during differentiation, whereas ABCG1 protein was barely detectable throughout differentiation (Figure IB and IC in the online-only Data Supplement). Preadipocytes supported efflux to HDL3 but not to apoA-I ( Figure  5A and 5B). Induction of peroxisome proliferator-activated receptor-␥, adiponectin, and lipoprotein lipase was suppressed by TNF-␣, particularly in partially and fully differentiated adipocytes (Table 2 ). TNF-␣ had little effect on expression of transporters and no effect on cholesterol efflux in preadipocytes ( Figure 5A to 5C and Table 2 ). At day 5, however, TNF-␣ inhibited efflux to apoA-I and HDL3 ( Figure 5A and 5B) coincident with attenuation of ABCA1 and SR-BI protein expression ( Figure 5C and Table 2 ). By day 10, there was no significant effect of TNF-␣ on cholesterol efflux, consistent with a lesser effect on ABCA1 and SR-BI in fully differentiated adipocytes ( Figure 5A to 5C and Table 2 ).
Finally, we assessed the effects of inflammation on mouse adipose expression of cholesterol transporters in vivo. Endotoxin administration (10 g/kg IV) downregulated adipose levels of SR-BI and ABCA1 mRNA and protein, with little effect on ABCG1 (Table II and Figure IID in the online-only Data Supplement).
Discussion
Adipose tissue harbors a major pool of free cholesterol, 18 but its role in regulating circulating HDL-C is poorly understood. In this work, we present the first evidence that adipocytes transfer cholesterol to HDL in vivo as well as in vitro. We identified a differentiation-dependent role for ABCA1 and Plasma was depleted of apolipoprotein B-containing lipoproteins by polyethylene glycol precipitation; counts in plasma before and after polyethylene glycol precipitation were determined, and the percent counts in HDL fraction were calculated. Data are presented as meanϮSEM; nϭ3 for in vivo studies of apoA-I modulation, adipocyte ABCA1 deletion, and adipocyte SR-BI deletion. SR-BI, but not ABCG1, in adipocyte cholesterol efflux to apoA-I and mature HDL, respectively, and provide experimental evidence that both ABCA1 and SR-BI can regulate adipocyte cholesterol transfer to HDL in vivo. Finally, we show that adipocyte inflammation downregulates transporters and impairs adipocyte cholesterol efflux to HDL. Because adipose inflammation is a hallmark of central obesity and type 2 diabetes mellitus, loss of adipocyte lipidation of HDL may directly contribute to lower HDL-C in these adipose inflammatory states.
Lipidation of HDL particles in vivo involves the coordinated effect of several tissues 6,7 likely involving cell-specific transporter functions. ABCA1 plays a major role in generation of nascent HDL particles 5, 36 and maintenance of plasma HDL-C through integrated hepatic and peripheral tissue actions. Dramatic reductions in HDL-C levels are observed in the absence of ABCA1 6,7 primarily because of loss of hepatic lipidation of liver-secreted apoA-I. However, peripheral ABCA1 also contributes to HDL-C 6 through intestinal 7 and brain 37 ABCA1. Although macrophage cholesterol efflux to HDL plays a major role in attenuating atherosclerosis, macrophages contain a very small pool of cholesterol and do not regulate circulating HDL-C in vivo. 4 Because adipose tissue contains a large pool of free cholesterol, 15, 16 we hypothesized that adipocytes may play a unique role in cholesterol transfer to HDL both in vitro and in vivo. In fact, a role for adipose or involvement of non-ABCA1 transporters in peripheral lipidation of HDL has not been demonstrated.
Our findings support a model of adipocyte-specific regulation of cholesterol efflux to HDL acceptors. We identified a role for ABCA1 and SR-BI transporters in efflux to apoA-I and HDL, respectively, and demonstrated marked upregulation of these proteins during adipocyte differentiation. Although ABCG1 promotes macrophage cholesterol efflux to mature HDL, 8, 9, 38 we found no evidence that ABCG1 protein is expressed in mature adipocytes or plays a role in adipocyte cholesterol efflux to HDL.
Using a modified version of our published macrophage-to-HDL RCT model, 12, 26 we demonstrate that adipocytes are capable of transferring cholesterol to circulating HDL. Indeed, the time course and extent of cholesterol label movement onto HDL were similar to those of macrophages 26, 39, 40 . Figure 5 . The effect of TNF-␣ (10 ng/mL) on cholesterol efflux from 3T3L1 cells during differentiation was assessed at day 0 (preadipocyte), day 5 (partially differentiated), and day 10 (mature). Cells were labeled with 3 H-cholesterol overnight before equilibration ϮTNF-␣ (10 ng/mL). Efflux to apoA-I (20 g/mL) (A) and HDL3 (50 g/mL) (B) at days 0, 5, and 10 ϮTNF-␣ are presented. C, Effects of TNF-␣ vs saline on ABCA1, ABCG1, and SR-BI protein levels at days 0, 5, and 10. 21 showed that primary adipocytes, isolated from rabbits fed a high-cholesterol diet or treated with statins, had altered cholesterol efflux to HDL that correlated with changes in SR-BI expression. They did not prove, however, that SR-BI was causal. Verghese and colleagues 42 demonstrated that enhanced adipocyte cholesterol efflux to HDL occurs during lipolysis without change in SR-BI and ABCA1 expression. It is possible, however, that modulation of transporter function [45] [46] [47] or membrane localization 40 rather than change in protein level could mediate this efflux. Our studies provide novel data that go beyond prior correlative studies. We addressed directly the role of specific transporters and performed in vivo studies examining the potential for adipocytes and specific transporters to transfer cholesterol to HDL in vivo. Future work with adipose-specific, conditional modulation of ABCA1 and SR-BI in rodent models is required to confirm the importance of these transporters and adipose regulation of HDL-C mass in vivo.
Our in vivo experimental model has limitations, including its nonphysiological nature, use of exogenous cells, and reliance on cholesterol tracer rather than mass. The peritoneal space is a convenient experimental location in which cells are exposed to extracellular fluid that has many of the characteristics of extracellular fluid in other tissues. Importantly, this model has provided fundamental insights into the macrophage RCT process. 12, 26 Work by Sehayek and Hazen 48 demonstrates that the subcutaneous administration of macrophages provides a pattern of RCT similar to that of the peritoneal cavity, arguing against any unique properties for the peritoneum. Although adipocytes do not occur as single cells in the peritoneum, intraperitoneal injection of labeled adipocytes resulted in cholesterol label movement to plasma HDL that was remarkably similar to that published for macrophages. Therefore, we doubt that there is a systematic difference between adipocytes and macrophages in the intraperitoneal model.
We examined the impact of an inflammatory adipocytokine on adipocyte cholesterol efflux to explore whether loss of adipocyte HDL lipidation is a possible mechanism for reduced HDL-C in adipose inflammatory settings. 33, 49 Because adipocyte susceptibility to inflammation 34, 35 depends on adipocyte maturity, we examined TNF-␣ effects during differentiation. TNF-␣ impaired cholesterol efflux most in partially differentiated adipocytes coincident with greatest suppression of ABCA1 and SR-BI. This is consistent with work by Chung et al, 34 who reported that endotoxin impaired glucose transport maximally in partially differentiated adipocytes. We also found that endotoxemia downregulated adipose SR-BI and ABCA1 in vivo. Thus, despite increased adipose mass and adipose cholesterol in obesity, attenuation of adipocyte-mediated HDL lipidation may directly contribute to lower HDL-C in metabolic syndrome and type 2 diabetes mellitus ( Figure 6 ).
In conclusion, adipocytes support transfer of cholesterol to HDL in vivo This process is mediated by ABCA1 and SR-BI, Figure 6 . Because adipose inflammation is a hallmark of central obesity and type 2 diabetes mellitus, loss of adipocyte lipidation of HDL may contribute directly to lower HDL-C levels in these inflammatory, insulin-resistant states. Despite greater adipose mass and cholesterol content in adiposity, adipocyte inflammation is associated with reduced expression of the cholesterol efflux transporters ABCA1 and SR-BI and impaired cholesterol efflux to apoA-I and HDL particles. IL-6 indicates interleukin-6.
but not ABCG1, and is attenuated in inflamed adipocytes. Our findings suggest adipocyte-specific cholesterol transporter functions and a role for mature adipose in maintenance of HDL-C levels. Conversely, adipose inflammation may attenuate adipocyte lipidation of HDL, leading to lower HDL-C in metabolic syndrome and type 2 diabetes mellitus.
